Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells.

MLA

Hour, Mann-Jen, et al. “Efficacy of HMJ-38, a New Quinazolinone Analogue, against the Gemcitabine-Resistant MIA-PaCa-2 Pancreatic Cancer Cells.” BioMedicine, vol. 13, no. 4, Dec. 2023, pp. 20–31. EBSCOhost, https://doi.org/10.37796/2211-8039.1423.

APA

Hour, M.-J., Tsai, F.-J., Lai, I.-L., Tsao, J.-W., Chiang, J.-H., Chiu, Y.-J., Lu, H.-F., Juan, Y.-N., Yang, J.-S., & Tsai, S.-C. (2023). Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells. BioMedicine, 13(4), 20–31. https://doi.org/10.37796/2211-8039.1423

Chicago

Hour, Mann-Jen, Fuu-Jen Tsai, I-Lu Lai, Je-Wei Tsao, Jo-Hua Chiang, Yu-Jen Chiu, Hsing-Fang Lu, Yu-Ning Juan, Jai-Sing Yang, and Shih-Chang Tsai. 2023. “Efficacy of HMJ-38, a New Quinazolinone Analogue, against the Gemcitabine-Resistant MIA-PaCa-2 Pancreatic Cancer Cells.” BioMedicine 13 (4): 20–31. doi:10.37796/2211-8039.1423.